Your browser doesn't support javascript.
loading
Evaluation of Outcomes of Mucinous Ovarian Cancer Treated at a Tertiary Care Cancer Hospital in Pakistan.
Hamdani, Syed Abdul Mannan; Azhar, Musa; Wahab, Abdul; Yasmeen, Tahira; Siddiqui, Neelam.
Afiliação
  • Hamdani SAM; Department of Medical Oncology, Shaukat Khanum Cancer Hospital, Lahore, Pakistan.
  • Azhar M; Department of Medical Oncology, Shaukat Khanum Cancer Hospital, Lahore, Pakistan.
  • Wahab A; Department of Medical Oncology, Shaukat Khanum Cancer Hospital, Lahore, Pakistan.
  • Yasmeen T; Department of Medical Oncology, Shaukat Khanum Cancer Hospital, Lahore, Pakistan.
  • Siddiqui N; Department of Medical Oncology, Shaukat Khanum Cancer Hospital, Lahore, Pakistan.
South Asian J Cancer ; 12(1): 81-86, 2023 Jan.
Article em En | MEDLINE | ID: mdl-36860587
ABSTRACT
Syed Abdul Mannan HamdaniObjective To evaluate the clinicopathological features and survival outcomes of mucinous ovarian cancer (MOC) patients in an Asian population. Study Design Descriptive observational study. Place and Duration of Study Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan, from January 2001 to December 2016. Methods Data of MOC were evaluated for demographics, tumor stage, clinical characteristics, tumor markers, treatment modalities, and outcomes from electronic Hospital Information System. Results Nine-hundred patients with primary ovarian cancer were reviewed, out of which 94 patients (10.4%) had MOC. The median age was 36 ± 12.4 years. The most common presentation was abdominal distension 51 (54.3%), while the rest presented with abdominal pain and irregular menstruation. Using FIGO (The International Federation of Gynecology and Obstetrics) staging, 72 (76.6%) had stage I, 3 (3.2%) stage II, stage III in 12 (12.8%), and 7 (7.4%) had stage IV disease. The majority of patients 75 (79.8%) had early-stage (stage I/II), while 19 (20.2%) presented with advanced-stage (III & IV). The median follow-up duration was 52 months (range 1-199 months). Among patients with early-stage (I&II), 3- and 5-year progression-free survival (PFS) was 95%, while for advanced stage (III&IV), PFS was 16% and 8%, respectively. The overall survival (OS) in early-stage I&II was 97%, while for advanced stages III & IV, the OS was 26%. Conclusion MOC is a challenging and rare subtype of ovarian cancer requiring special attention and recognition. Most patients treated at our center presented with early stages and had excellent outcomes, while advanced-stage disease had dismal results.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article